This event has passed.

Thursday, January 17th

7:00PM – Pre Registration & Welcome Reception (Community Room)

Friday, January 18th

7:00AM – Registration & Breakfast (Paradise Terrace)

8:00AM – Opening Remarks (Paradise Ballroom South)

8:10AM – Keynote Address: POAG – When Does the Typical Become Atypical

  • Dr. Louis Pasquale
  • Discussion

8:40AM – Retinal Procedures and Glaucoma (Moderator: Lisa Gould)

  • Bevacizumab and Glaucoma – Steven Schendel
  • Post Pars Plana Vitrectomy Glaucoma – Victor Penner
  • Discussion

9:05AM – Keynote Address: Treating IOP with New Mechanisms

  • Dr. Louis Pasquale
  • Discussion

9:45AM – Health Break

10:15AM – Surgical Challenges (Moderator: James Taylor)

  • Tube Erosion, Approach and Risk Factors – Toby Chan
  • Cataract SX in Presence of a Bleb – Caroline Lajoie
  • Nanophthalmos and Scleral Windows – Aloa Mofti
  • Bleb Dysesthesia – Toby Chan
  • Discussion

11:15AM – Glaucoma Research in Canada (Moderator: Catherine Birt)

  • Foundation for Fighting Blindness – Mary Sunderland
  • Update on The Glaucoma Research Society of Canada – Graham Trope
  • Proposal for a Canadian NSAIDS Study – Cindy Hutnik
  • Proposal for a Canadian PXF Trial – Jayme Vianna
  • Discussion

12:00PM – Lunch (Paradise Terrance)

12:45PM – 1:30PM – CGS Business Meeting (Paradise Ballroom South)

1:30PM – 2:30PM – Wet Labs (Paradise Ballroom North)

6:00PM – 10:00PM – CGS Reception & Dinner (Mountain Shadows Lawn)

Saturday, January 19th

7:00AM – Breakfast (Paradise Terrace)

8:00AM – Keynote Address: Artificial Intelligence – Addressing Gaps in Glaucoma Care

  • Dr. Louis Pasquale
  • Discussion

8:30AM – Imaging and Glaucoma (Moderator: Bryce Ford)

  • OCT – Red Disease – Green Disease – Edward Moss
  • OCT – Angio in Glaucoma – Marcelo Nicolela


8:50AM – Glaucoma Inside and Out (Moderator: Lisa Heckler)

  • Teleglaucoma – How to Get Started – Kenman Gan
  • “The Human Side of Glaucoma Care” – Marianne Edwards
  • Discussion

9:30AM – Keynote Address: Exfoliation Syndrome: Facts and Fiction

  • Dr. Louis Pasquale
  • Discussion

9:50AM – Health Break

10:20AM – MIGS – Evolving or Dissolving? (Moderator: Hady Saheb)

  • Stents and Trabecular Incisions – Paul Harasymowycz
  • Is There a Role for iStents in Patients Other than POAG? – Michael Dorey
  • 180 vs. 360 GATT – Patrick Gooi
  • Ab Externo Technique for Xen – David Yan
  • Innfocus Revision Data – Jing Wang
  • Optimal Use Protocol for MIGS – Cindy Hutnik
  • MIGS – Show Me the Evidence – Yvonne Buys
  • Discussion

12:10PM – Cypass Panel (Moderator: Andrew Crichton)

  • Panel Members: Hady Saheb, Steven Schendel
  • Discussion

12:30PM – Concluding Remarks

Dr. Louis R. Pasquale, MD, FARVO

Louis R. Pasquale, MD, FARVO, is Site Chair of the Department of Ophthalmology at The Mount Sinai Hospital and Mount Sinai Queens. In addition, he serves as the Vice Chair of Translational Ophthalmology Research for the Mount Sinai Health System.

A native New Yorker, Dr. Pasquale joined the Mount Sinai Health System after a 25-year career at the Massachusetts Eye and Ear Infirmary, a teaching hospital of Harvard Medical School. There, he rose to the rank of Professor of Ophthalmology and Distinguished Scholar in Ophthalmology. In addition, he co-directed the Glaucoma Center of Excellence and directed the Glaucoma Service, the Glaucoma Fellowship Program, and the Teleretinal Program.

Dr. Pasquale has garnered international recognition for his research achievements and has given numerous named lectures and keynote presentations throughout the world. As a Principal Investigator, he has received continuous support from the National Institutes of Health since 2006. His research takes advantage of the rich resources available in the Nurses Health Study, the Health Professional Follow-up Study, and the Women’s Genome Health Study to focus on the discovery of primary prevention strategies in open-angle glaucomas. His work has highlighted environmental risk factors for exfoliation syndrome, the most common form of secondary open-angle glaucoma, and the role nitric oxide signaling plays in the pathogenesis of primary open-angle glaucoma. He has also contributed to resolving the complex genetic architecture of primary open-angle glaucoma.

Dr. Pasquale is a member of the editorial boards of PLOS One, Journal of Glaucoma, Ophthalmology Glaucoma, International Glaucoma Review, Asia-Pacific Journal of Ophthalmology, and the American Journal of Ophthalmology. He serves as Chair of the American Glaucoma Society Research Committee and is a member of the National Institutes of Health’s National Advisory Eye Council. He is the Association for Research in Vision and Ophthalmology (ARVO) Glaucoma Section Trustee and a Gold Fellow of ARVO.  Additionally, he is a member of the American Ophthalmological Society and the Glaucoma Research Society.

Dr. Pasquale earned his medical degree at the State University of New York Stony Brook School of Medicine. He completed an internal medicine internship at Bronx Municipal Hospital, an ophthalmology residency at Temple University Hospital, and a two-year fellowship in glaucoma at Johns Hopkins School of Medicine.

Learning Objectives

Overall Meeting Objectives

Upon conclusion of the CGS Meeting, attendees will be able to:

–    Describe new mechanisms of action for lowering the intraocular pressure medically

–    Identify common vitreoretinal procedures and current theories behind their association with glaucoma

–  Explain the potential of new emerging technologies/systems (OCT, AI, teleglaucoma) in addressing the gaps in glaucoma care

–    Integrate surgical pearls for common surgical complications into my practice

–    Apply new techniques for emerging and evolving surgical procedures

Keynote Address Objectives:

1) When Does the Typical Become Atypical

  • Acquire a deeper understanding of POAG a heterogenous group of diseases, by being provided with three pearls about distinct subtypes of POAG:

Pearl 1: Paracentral open angle glaucoma needs low target IOPs

Pearl 2: Insist on examining the children of African-derived OAG because they get the disease 1 or 2 decades before their Caucasian counterparts

Pearl 3: Resist the mega work up of the young patient with myopia-related OAG. This is truly an inherent optic nerve degeneration.

2) Treating IOP with New Mechanisms of Action

  • Recognize three new mechanisms in lowering IOP medically i.e.

1. Nitric oxide, an endothelial-derived gasomitter lowers IOP directly.

2. Latanoprostene bunod acts upstream and netarsudil works downstream in the nitric oxide signaling pathway.

3. Nitric oxide signaling molecules contribute to the IOP level as well the inherent vulnerability to optic nerve degeneration.

3) Addressing Gaps in Glaucoma Care

  • Attendees will recognize 3 gaps in glaucoma addressed by artificial intelligence (AI):

1.     Gap 1: Optic nerve disease categorized by excavation and erosion of the neuroretinal rim that clinically manifests itself by increased optic nerve head (ONH) cupping

2.     Gap 2:  Outputs from visual field tests typically provide reliability parameters, age-matched normative comparisons and summary global indices, but more detailed analysis of this functional data is lacking.

3.     Gap 3: Understanding how and why AI algorithms can detect VF progression earlier than conventional computer strategies and produces results that are more in line with clinical ground truth.

Additional Session Objectives

By the end of this meeting, participants will be able to:

–    Describe and understand the effect of bevacizumab injections on the trabecular meshwork

–    Assess the pathogenesis and detect secondary glaucoma post pars plana vitrectomy surgery

–    Examine the link between pars plana vitrectomy and the development of open angle glaucoma

–    Discuss the current theories behind the association of glaucoma and pars plana vitrectomy

–    Describe strategies to assist in early detection of glaucoma secondary to pars plana glaucoma

– Apply techniques for surgical challenges such as tube erosion, bleb dysesthesia, bleb failure after phacoemulsification and revisions for MIGS devices

–    Integrate into my practice surgical pearls for common surgical complications

–    Interpret clinical tools and resources needed to develop a teleglaucoma program

–    -Develop a deeper understanding of the human side of glaucoma care including the moral dilemmas faced by physicians and patients

–    Apply new techniques for emerging and evolving surgical procedures

–    Demonstrate understanding of the current projects and ideas being funded by The Glaucoma Research Society of Canada

–    Express understanding of current research projects

–    Describe the goals and objectives of the Foundation for Fighting Blindness

-Identify the differences between OCT Red disease and green disease and its potential causes

–    Apply techniques for surgical challenges such as tube erosion, bleb dysesthesia, bleb failure after phacoemulsification and revisions for MIGS devices

–    Integrate into my practice surgical pearls for common surgical complications

–   Analyze the roles for stent and trabecular incisions in open angle glaucoma, as well as other types of glaucoma.

-Describe and identify current controversies regarding the role for MIGS and will be able to discuss the evidence ( or lack of ) for MIGS in the management of glaucoma

-Identify the Optimal Use protocol for MIGS in Ontario and be able to discuss the ethical and cost effectiveness issues surrounding MIGS in addition to the evidence regarding its clinical effectiveness

–    Describe current options for cyclodestructive procedures

–    Compare various modalities of treatment for angle closure

–    Describe new advances in the surgical management of glaucoma